Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 2
2012 1
2014 1
2015 2
2016 1
2017 2
2018 1
2022 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Optimisation of treatments for oral Neisseria gonorrhoeae infection: Pharmacokinetics Study (STI-PK project) - study protocol for non-randomised clinical trial.
Kong FYS, Unemo M, Lim SH, Latch N, Williamson DA, Roberts JA, Wallis SC, Parker SL, Landersdorfer CB, Yap T, Fairley CK, Chow EPF, Lewis DA, Hammoud MA, Hocking JS. Kong FYS, et al. Among authors: latch n. BMJ Open. 2022 Nov 11;12(11):e064782. doi: 10.1136/bmjopen-2022-064782. BMJ Open. 2022. PMID: 36368750 Free PMC article. Clinical Trial.
Loss to follow-up in the Australian HIV Observational Database.
McManus H, Petoumenos K, Brown K, Baker D, Russell D, Read T, Smith D, Wray L, Giles M, Hoy J, Carr A, Law MG; Australian HIV Observational Database. McManus H, et al. Antivir Ther. 2015;20(7):731-41. doi: 10.3851/IMP2916. Epub 2014 Nov 7. Antivir Ther. 2015. PMID: 25377928 Free PMC article.
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group. Pett SL, et al. Clin Infect Dis. 2016 Jul 1;63(1):122-32. doi: 10.1093/cid/ciw207. Epub 2016 Apr 5. Clin Infect Dis. 2016. PMID: 27048747 Free PMC article. Clinical Trial.
Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group. Pett SL, et al. HIV Med. 2018 Jan;19(1):65-71. doi: 10.1111/hiv.12532. Epub 2017 Jul 13. HIV Med. 2018. PMID: 28703491 Free article. Clinical Trial.